# Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)

> **NCT00509145** · PHASE3 · COMPLETED · sponsor: **Teva Branded Pharmaceutical Products R&D, Inc.** · enrollment: 1106 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Laquinimod
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT00509145
- **Lead sponsor:** Teva Branded Pharmaceutical Products R&D, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-11-13
- **Primary completion:** 2010-11-08
- **Final completion:** 2010-11-08
- **Target enrollment:** 1106 (ACTUAL)
- **Last updated:** 2021-11-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509145

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509145, "Safety and Efficacy of Orally Administered Laquinimod Versus Placebo for Treatment of Relapsing Remitting Multiple Sclerosis (RRMS)". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT00509145. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*